Gene therapy readout helps Ultragenyx rebound

Orphan disease company Ultragenyx added nearly $600 million in market cap Friday after reporting better-than-expected data for gene therapy DTX301 -- a welcome lift after clinical disappointments had weighed on the stock in 2H19.

After market

Read the full 358 word article

User Sign In